Edwards Lifesciences Corporation (EW)
NYSE: EW · Real-Time Price · USD
71.39
-0.23 (-0.32%)
At close: Mar 3, 2025, 4:00 PM
71.80
+0.41 (0.57%)
Pre-market: Mar 4, 2025, 5:46 AM EST
Edwards Lifesciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 5,440 | 6,005 | 5,382 | 5,233 | 4,386 | Upgrade
|
| Revenue Growth (YoY) | -9.41% | 11.56% | 2.86% | 19.29% | 0.88% | Upgrade
|
| Cost of Revenue | 1,118 | 1,380 | 1,079 | 1,249 | 1,081 | Upgrade
|
| Gross Profit | 4,322 | 4,625 | 4,304 | 3,984 | 3,306 | Upgrade
|
| Selling, General & Admin | 1,789 | 1,823 | 1,567 | 1,494 | 1,229 | Upgrade
|
| Research & Development | 1,053 | 1,072 | 945.2 | 903.1 | 760.7 | Upgrade
|
| Other Operating Expenses | -0.3 | - | - | - | - | Upgrade
|
| Operating Expenses | 2,842 | 2,895 | 2,512 | 2,397 | 1,990 | Upgrade
|
| Operating Income | 1,480 | 1,730 | 1,792 | 1,587 | 1,316 | Upgrade
|
| Interest Expense | - | -17.6 | -19.2 | -18.4 | -15.8 | Upgrade
|
| Interest & Investment Income | 100.5 | 67.2 | 35.5 | 17.4 | 23.4 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | 0.9 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 10.5 | -1.2 | 5 | 12.3 | Upgrade
|
| Other Non Operating Income (Expenses) | 68.9 | 11.5 | 18.8 | 10.8 | -1 | Upgrade
|
| EBT Excluding Unusual Items | 1,650 | 1,801 | 1,826 | 1,601 | 1,336 | Upgrade
|
| Merger & Restructuring Charges | -61 | - | -62.3 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -8.8 | -19.9 | -2.8 | -0.3 | Upgrade
|
| Legal Settlements | -40.4 | -203.5 | -15.8 | -20.6 | -405.4 | Upgrade
|
| Other Unusual Items | - | 9 | 35.8 | 124.1 | -13.6 | Upgrade
|
| Pretax Income | 1,548 | 1,598 | 1,767 | 1,702 | 916.7 | Upgrade
|
| Income Tax Expense | 152.1 | 198.7 | 245.5 | 198.9 | 93.3 | Upgrade
|
| Earnings From Continuing Operations | 1,396 | 1,399 | 1,522 | 1,503 | 823.4 | Upgrade
|
| Earnings From Discontinued Operations | 2,774 | - | - | - | - | Upgrade
|
| Net Income to Company | 4,170 | 1,399 | 1,522 | 1,503 | 823.4 | Upgrade
|
| Minority Interest in Earnings | 4.9 | 3 | - | - | - | Upgrade
|
| Net Income | 4,175 | 1,402 | 1,522 | 1,503 | 823.4 | Upgrade
|
| Net Income to Common | 4,175 | 1,402 | 1,522 | 1,503 | 823.4 | Upgrade
|
| Net Income Growth | 197.68% | -7.85% | 1.25% | 82.55% | -21.35% | Upgrade
|
| Shares Outstanding (Basic) | 598 | 607 | 619 | 623 | 623 | Upgrade
|
| Shares Outstanding (Diluted) | 599 | 609 | 624 | 631 | 632 | Upgrade
|
| Shares Change (YoY) | -1.66% | -2.37% | -1.11% | -0.11% | -0.75% | Upgrade
|
| EPS (Basic) | 6.98 | 2.31 | 2.46 | 2.41 | 1.32 | Upgrade
|
| EPS (Diluted) | 6.97 | 2.30 | 2.44 | 2.38 | 1.30 | Upgrade
|
| EPS Growth | 202.97% | -5.74% | 2.52% | 83.08% | -20.73% | Upgrade
|
| Free Cash Flow | - | 642.8 | 973.6 | 1,406 | 647.3 | Upgrade
|
| Free Cash Flow Per Share | - | 1.05 | 1.56 | 2.23 | 1.02 | Upgrade
|
| Gross Margin | 79.46% | 77.02% | 79.96% | 76.13% | 75.36% | Upgrade
|
| Operating Margin | 27.21% | 28.81% | 33.29% | 30.32% | 30.01% | Upgrade
|
| Profit Margin | 76.75% | 23.35% | 28.28% | 28.73% | 18.77% | Upgrade
|
| Free Cash Flow Margin | - | 10.70% | 18.09% | 26.88% | 14.76% | Upgrade
|
| EBITDA | 1,630 | 1,875 | 1,932 | 1,721 | 1,423 | Upgrade
|
| EBITDA Margin | 29.97% | 31.22% | 35.89% | 32.90% | 32.45% | Upgrade
|
| D&A For EBITDA | 150.13 | 144.9 | 139.6 | 134.8 | 107.2 | Upgrade
|
| EBIT | 1,480 | 1,730 | 1,792 | 1,587 | 1,316 | Upgrade
|
| EBIT Margin | 27.21% | 28.81% | 33.29% | 30.32% | 30.01% | Upgrade
|
| Effective Tax Rate | 9.82% | 12.43% | 13.89% | 11.69% | 10.18% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.